Biotech Stocks To Consider – July 27th

Thermo Fisher Scientific, Danaher, AbbVie, Bloom Energy, Vertex Pharmaceuticals, IQVIA, and Veeva Systems are the seven Biotech stocks to watch today, according to MarketBeat’s stock screener tool. Biotech stocks are shares of publicly traded companies that use biological processes, such as genetic engineering and molecular biology, to develop products in health care, agriculture, and environmental science. These companies often invest heavily in research and development of new drugs, therapies, diagnostics, and biologics. Because their success hinges on clinical trial outcomes, regulatory approvals, and scientific breakthroughs, biotech stocks can experience high volatility and reward. These companies had the highest dollar trading volume of any Biotech stocks within the last several days.

Thermo Fisher Scientific (TMO)

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Thermo Fisher Scientific stock traded up $3.58 during mid-day trading on Friday, hitting $478.61. The company had a trading volume of 4,191,526 shares, compared to its average volume of 3,108,119. The stock has a market cap of $180.67 billion, a price-to-earnings ratio of 27.68, a PEG ratio of 2.48 and a beta of 0.77. Thermo Fisher Scientific has a 1 year low of $385.46 and a 1 year high of $627.88. The company has a quick ratio of 1.38, a current ratio of 1.93 and a debt-to-equity ratio of 0.65. The business has a fifty day moving average of $413.76 and a 200 day moving average of $469.70.

Danaher (DHR)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Shares of DHR stock traded up $2.79 during trading hours on Friday, hitting $205.60. The stock had a trading volume of 5,355,676 shares, compared to its average volume of 3,965,185. The firm has a market capitalization of $147.22 billion, a PE ratio of 43.74, a PEG ratio of 2.86 and a beta of 0.77. Danaher has a twelve month low of $171.00 and a twelve month high of $281.70. The stock’s 50 day moving average is $196.38 and its 200 day moving average is $203.68. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.62 and a quick ratio of 1.05.

AbbVie (ABBV)

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.

Shares of ABBV stock traded down $0.61 during trading hours on Friday, hitting $190.22. The stock had a trading volume of 3,786,155 shares, compared to its average volume of 6,461,288. The company has a debt-to-equity ratio of 44.14, a current ratio of 0.76 and a quick ratio of 0.64. The stock’s 50 day moving average is $187.62 and its 200 day moving average is $189.77. AbbVie has a twelve month low of $163.81 and a twelve month high of $218.66. The firm has a market capitalization of $336.00 billion, a PE ratio of 80.94, a PEG ratio of 1.26 and a beta of 0.48.

Bloom Energy (BE)

Bloom Energy Corporation designs, manufactures, sells, and installs solid-oxide fuel cell systems for on-site power generation in the United States and internationally. The company offers Bloom Energy Server, a solid oxide technology that converts fuel, such as natural gas, biogas, hydrogen, or a blend of these fuels into electricity through an electrochemical process without combustion.

Shares of NYSE BE traded up $1.31 during mid-day trading on Friday, hitting $34.37. 16,423,808 shares of the company were exchanged, compared to its average volume of 9,213,165. The company has a quick ratio of 2.39, a current ratio of 3.44 and a debt-to-equity ratio of 2.07. The stock has a 50 day simple moving average of $22.78 and a 200-day simple moving average of $22.01. Bloom Energy has a 1-year low of $9.02 and a 1-year high of $34.78. The firm has a market cap of $7.98 billion, a price-to-earnings ratio of -687.26 and a beta of 3.22.

Vertex Pharmaceuticals (VRTX)

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

Shares of NASDAQ VRTX traded down $2.62 during mid-day trading on Friday, hitting $469.65. 1,176,853 shares of the company were exchanged, compared to its average volume of 1,076,910. Vertex Pharmaceuticals has a 1-year low of $377.85 and a 1-year high of $519.88. The company has a quick ratio of 2.29, a current ratio of 2.65 and a debt-to-equity ratio of 0.01. The stock has a 50 day simple moving average of $453.13 and a 200-day simple moving average of $465.05. The firm has a market cap of $120.61 billion, a price-to-earnings ratio of -119.81 and a beta of 0.41.

IQVIA (IQV)

IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

IQVIA stock traded down $1.65 during midday trading on Friday, reaching $199.17. The company’s stock had a trading volume of 2,138,911 shares, compared to its average volume of 2,283,775. IQVIA has a fifty-two week low of $134.65 and a fifty-two week high of $252.88. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.82 and a current ratio of 0.84. The stock’s 50 day simple moving average is $157.09 and its 200 day simple moving average is $170.27. The firm has a market capitalization of $33.86 billion, a PE ratio of 28.82, a P/E/G ratio of 2.20 and a beta of 1.30.

Veeva Systems (VEEV)

Veeva Systems Inc. provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.

Veeva Systems stock traded down $0.52 during midday trading on Friday, reaching $290.73. The company’s stock had a trading volume of 1,210,059 shares, compared to its average volume of 1,228,931. Veeva Systems has a fifty-two week low of $177.41 and a fifty-two week high of $294.00. The firm has a market capitalization of $47.51 billion, a PE ratio of 61.60, a P/E/G ratio of 2.30 and a beta of 0.98. The stock’s 50 day simple moving average is $275.05 and its 200 day simple moving average is $244.47.